Cancer Vaccines Market Anticipates Impressive Growth Trajectory at a CAGR of 36% During the Forecast Period (2026-2036)

{
  "signal_id": "582bd54d-0d55-f126-2e66-9187bdeffb42",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-09-21T14:31:00+00:00",
  "company": {
    "name": "Moderna",
    "domain": "modernatx.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/cancer-vaccines-market-anticipates-impressive-growth-trajectory-at-a-cagr-of-36-during-the-forecast-period-20262036--delveinsight-302884287.html",
    "title": "Cancer Vaccines Market Anticipates Impressive Growth Trajectory at a CAGR of 36% During the Forecast Period (2026-2036) | DelveInsight",
    "excerpt": "The growth of the cancer vaccine market is expected to be mainly driven by increasing incidence, rising awareness and access to treatment, and the emergence of novel therapies such as OSE2101 (OSE Immunotherapeutic), Intismeran autogene (Merck/Moderna Therapeutics), CYLEMBIO (IO102-IO103) IO Biotech), Galinpepimut S (SELLAS Life Sciences), BNT113 (BioNTech), RP2 (Replimune), and others. LAS VEGAS , Sept. 21, 2026 /PRNewswire/ -- DelveInsight's Cancer Vaccines Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Melanoma, Lung Cancer (NSCLC), Bladder Cancer, Prostate Cancer, Breast Cancer, Pancreatic Cancer, Head and Neck Cancer, Cervical Cancer, and Other Solid Tumors. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging cancer vaccines, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets (the US, EU4, UK, and Japan). Key Takeaways from the Cancer Vaccines Market Report Discover the latest studies on cancer vaccines 2026 @ https://www.delveinsight.com/report-store/cancer-vaccines-market Key Factors Driving the Cancer Vaccines Market Sadaf Javed...",
    "product": "Intismeran autogene",
    "summary": "Moderna Therapeutics and Merck are co-developing Intismeran autogene, a personalized mRNA-based cancer therapy, and are advancing its clinical development program across multiple tumor types.",
    "planning": true,
    "image_url": "https://mmx.prnewswire.com/media/MS1196378/logo-png.jpg?id=OA2959513&p=facebook",
    "confidence": 0.9,
    "product_data": {
      "name": "Intismeran autogene",
      "full_text": "Intismeran autogene (Merck/Moderna Therapeutics)",
      "fuzzy_match": false
    },
    "product_tags": [
      "general_technology",
      "medical",
      "future_tech"
    ],
    "published_at": "2026-09-21T14:31:00Z",
    "article_sentence": "Moderna Therapeutics and Merck's Intismeran autogene is an investigational, personalized mRNA-based Individualized Neoantigen Therapy (INT) that incorporates synthetic mRNA encoding up to 34 patient-specific neoantigens identified from an individual tumor.",
    "related_company_name": "Merck",
    "related_company_domain": "merck.com"
  }
}

curl https://signals.autobound.ai/v1/signals/582bd54d-0d55-f126-2e66-9187bdeffb42 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"modernatx.com","limit":20}'